Century Therapeutics, Inc. (IPSC) financial statements (2022 and earlier)

Company profile

Business Address 3675 MARKET STREET
PHILADELPHIA, PA 19104
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments222,879
Cash and cash equivalents56,445
Short-term investments166,434
Prepaid expense1,606
Other current assets250
Other undisclosed current assets3,419
Total current assets:228,154
Noncurrent Assets
Operating lease, right-of-use asset11,854
Property, plant and equipment57,967
Long-term investments and receivables135,914
Long-term investments135,914
Deposits noncurrent assets1,549
Restricted cash and investments1,717
Other undisclosed noncurrent assets220
Total noncurrent assets:209,221
TOTAL ASSETS:437,375
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,919
Accounts payable7,596
Accrued liabilities796
Employee-related liabilities4,445
Interest and dividends payable82
Debt1,039
Other undisclosed current liabilities1,697
Total current liabilities:15,655
Noncurrent Liabilities
Long-term debt and lease obligation23,462
Long-term debt, excluding current maturities8,903
Operating lease, liability14,559
Other undisclosed noncurrent liabilities(12,539)
Total noncurrent liabilities:25,482
Total liabilities:41,137
Stockholders' equity
Stockholders' equity attributable to parent396,238
Common stock5
Additional paid in capital785,049
Accumulated other comprehensive loss(650)
Accumulated deficit(388,166)
Total stockholders' equity:396,238
TOTAL LIABILITIES AND EQUITY:437,375

Income statement (P&L) ($ in thousands)

12/31/2021
Operating expenses(94,883)
Operating loss:(94,883)
Nonoperating expense
(Other Nonoperating expense)
(898)
Interest and debt expense(1,275)
Loss from continuing operations before equity method investments, income taxes:(97,056)
Other undisclosed income from continuing operations before income taxes1,275
Loss from continuing operations before income taxes:(95,781)
Income tax expense(43)
Net loss available to common stockholders, diluted:(95,824)

Comprehensive Income ($ in thousands)

12/31/2021
Net loss:(95,824)
Other comprehensive loss(615)
Comprehensive loss:(96,439)
Other undisclosed comprehensive loss, net of tax, attributable to parent(32)
Comprehensive loss, net of tax, attributable to parent:(96,471)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: